New name, new offices for blood services agency
The new year will see a new name and location for the Hemophilia Center of Western New York. The organization has rebranded as WNY Bloodcare, a name it says better reflects the range of blood disorders it serves.  While it will continue to serve individuals with hemophilia, its staff of hematologists, laboratory and specialty pharmacy professionals diagnoses and treats patients with a r ange of bleeding and clotting disorders. The agency has long been based at 936 Delaware Ave. and now plans… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - January 16, 2019 Category: Health Management Authors: Tracey Drury Source Type: news

Game-changing research reveals that parental experience is epigenetically imprinted onto 14 successive generations
(Natural News) We all know that we inherit certain specific genetic characteristics from our parents and that these are indelibly written in our DNA code. These genetic traits determine everything from the color of our eyes to whether or not we have dimples. Unfortunately, certain genetic diseases like cystic fibrosis and hemophilia can be passed... (Source: NaturalNews.com)
Source: NaturalNews.com - January 14, 2019 Category: Consumer Health News Source Type: news

Takeda/haemophilia: blood test
a breakthrough inIf gene therapy lives up to its promise, it reallywill justify the song and dance (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - December 5, 2018 Category: Pharmaceuticals Source Type: news

Roche says Hemlibra effective in pivotal study
Roche's Hemlibra provided sustained bleed control in the largest pivotal study to date of children with a form of haemophilia, the Swiss drugmaker said on Monday. (Source: Reuters: Health)
Source: Reuters: Health - December 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche ’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors
Roche today announced data from the primary analysis of the phase III HAVEN 2 study evaluating Hemlibra ® (emicizumab) prophylaxis in children younger than 12 years of age with haemophilia A with factor VIII inhibitors, including longer follow-up for once-weekly dosing and new data for less frequent dosing schedules (every two weeks or every four weeks). (Source: Roche Media News)
Source: Roche Media News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors
Roche today announced data from the primary analysis of the phase III HAVEN 2 study evaluating Hemlibra ® (emicizumab) prophylaxis in children younger than 12 years of age with haemophilia A with factor VIII inhibitors, including longer follow-up for once-weekly dosing and new data for less frequent dosing schedules (every two weeks or every four weeks). (Source: Roche Investor Update)
Source: Roche Investor Update - December 3, 2018 Category: Pharmaceuticals Source Type: news

St. Jude research into leukemia, sickle cell and other blood disorders presented at ASH
(St. Jude Children's Research Hospital) The 60th Annual Meeting of the American Society of Hematology will feature research from St. Jude Children's Research Hospital on topics ranging from the genomic basis and vulnerabilities of leukemia to an update on gene therapy for hemophilia B to advances in sickle cell disease and beta-thalassemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 30, 2018 Category: Cancer & Oncology Source Type: news

Bayer will shift hemophilia drug work to Berkeley, but won't add jobs
Bayer AG will cut 12,000 jobs globally and shut a recently constructed hemophilia drug-making facility in Germany, consolidating manufacturing of its blood-clotting drugs in Berkeley. Bayer has no plans to recall people to the roughly 400 manufacturing-related jobs it has cut over the past year in Berkeley, the only unionized biotech workforce in the United States. But the moves disclosed Thursday allow Bayer to mop up excess capacity in response to a more-competitive hemophili a market — including… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 29, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

Bayer will shift hemophilia drug work to Berkeley, but won't add jobs
Bayer AG will cut 12,000 jobs globally and shut a recently constructed hemophilia drug-making facility in Germany, consolidating manufacturing of its blood-clotting drugs in Berkeley. Bayer has no plans to recall people to the roughly 400 manufacturing-related jobs it has cut over the past year in Berkeley, the only unionized biotech workforce in the United States. But the moves disclosed Thursday allow Bayer to mop up excess capacity in response to a more-competitive hemophili a market — including… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 29, 2018 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

27.11.18: Not intended for U.S. and UK Media
Bayer receives EU approval for its hemophilia A treatment Jivi®The safety and efficacy profile of Jivi has been demonstrated in more than five years of clinical studies / Prophylaxis with Jivi enables sustained factor VIII concentrations in the blood over timemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 27, 2018 Category: Pharmaceuticals Source Type: news

Bayer receives EU approval for its hemophilia A treatment Jivi ® (for specialized target groups only)
The safety and efficacy profile of Jivi has been demonstrated in more than five years of clinical studies / Prophylaxis with Jivi enables sustained factor VIII concentrations in the blood over time (Source: Bayer Company News)
Source: Bayer Company News - November 27, 2018 Category: Pharmaceuticals Source Type: news

BioMarin sets stage early for hemophilia cure off-Broadway
BioMarin Pharmaceutical Inc is turning to the theater to establish its name with hemophilia patients, long before its experimental cure for the bleeding disorder could reach the market. (Source: Reuters: Health)
Source: Reuters: Health - November 21, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Harvey's gang: Haemophilia patient trades places with doctor
James McGleenan, 11, swaps places with his doctor to find out what happens when blood is taken. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 20, 2018 Category: Consumer Health News Source Type: news

Harvey's gang: 11-year-old haemophilia patient trades place with doctor
James McGleenan, 11, swaps places with his doctor to find out what happens when blood is taken. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 20, 2018 Category: Consumer Health News Source Type: news

Hemophilia, The Musical? It ’s Funded By Biotech BioMarin
Rare disease drug company BioMarin put on a show called ‘Hemophilia: The Musical’ performed by teenagers affected by blood disorders. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 16, 2018 Category: Pharmaceuticals Authors: Michela Tindera, Forbes Staff Source Type: news

Medical News Today: Hemophilia, coagulation, and blood clotting
If blood does not clot, life-threatening bleeding can occcur. Find out about how blood clots, how clotting factors work, and how treatment has improved the outlook for people with hemophilia. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 16, 2018 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Morning Break:'Hemophilia the Musical'; Another ARB Recall; Global Contraception Use
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 13, 2018 Category: American Health Source Type: news

Teenage haemophiliacs were called in groups to be told if they’d been infected with HIV
Almost all the dozens of photographs Adrian, 47, has catalogued from his youth show the faces of schoolfriends who have died, most before they were 30 years old. (Source: the Mail online | Health)
Source: the Mail online | Health - October 23, 2018 Category: Consumer Health News Source Type: news

FDA expands Roche hemophilia med approval
The drug, Hemlibra, won approval in the U.S. only for hemophilia A patients with factor VIII resistance, or inhibitors last year (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 8, 2018 Category: Pharmaceuticals Source Type: news

U.S. FDA Expands Indication for Roche's Bleeding Disorder Drug U.S. FDA Expands Indication for Roche's Bleeding Disorder Drug
Roche said on Thursday it received approval from U.S. regulators for its hemophilia A drug Hemlibra (emicizumab)for use in nearly all patients, as the Swiss drugmaker pushes deeper into diseases beyond cancer to replace revenue from older, patent-expired drugs.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 5, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Bayer union chief on Berkeley job cuts: 'It's going to be a long road'
After roughly 100 workers at Bayer AG's Berkeley manufacturing site opted in July to take a severance package — on top of another 100 or so who had volunteered in January to leave the company — the rank-and-file believed they had done their part to help the company reorganize its hemophilia drug business. Late Tuesday afternoon, as Bayer officials met with leaders of the International Longshore and War ehouse Union Local 6, they discovered they were wrong: The company laid out a plan to cut 227… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 5, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

Bayer union chief on Berkeley job cuts: 'It's going to be a long road'
After roughly 100 workers at Bayer AG's Berkeley manufacturing site opted in July to take a severance package — on top of another 100 or so who had volunteered in January to leave the company — the rank-and-file believed they had done their part to help the company reorganize its hemophilia drug business. Late Tuesday afternoon, as Bayer officials met with leaders of the International Longshore and War ehouse Union Local 6, they discovered they were wrong: The company laid out a plan to cut 227… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 5, 2018 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

FDA Approves Genentech ’s Hemlibra (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors
South San Francisco, CA -- October 4, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Hemlibra ® (emicizumab-kxwh) for routine prophylaxis to... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 4, 2018 Category: Drugs & Pharmacology Source Type: news

U.S. FDA expands approval of Roche hemophilia drug
Roche on Thursday said U.S. regulators approved expanded use of its hemophilia A drug Hemlibra to include nearly all patients, as the Swiss drugmaker increases its focus on diseases beyond cancer to help replace revenue from older products that have lost patent protection. (Source: Reuters: Health)
Source: Reuters: Health - October 4, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA expands approval of Roche's bleeding disorder drug
Roche said on Thursday U.S. regulators approved its hemophilia A drug Hemlibra, expanding its use in nearly all patients, as the Swiss drugmaker pushes deeper into diseases beyond cancer to replace revenue from older, patent-expired drugs. (Source: Reuters: Health)
Source: Reuters: Health - October 4, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves Roche ’s Hemlibra for haemophilia A without factor VIII inhibitors
Roche announced today that the US Food and Drug Administration (FDA) has approved Hemlibra ® (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with haemophilia A without factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - October 4, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Hemlibra for haemophilia A without factor VIII inhibitors
Roche announced today that the US Food and Drug Administration (FDA) has approved Hemlibra ® (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with haemophilia A without factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - October 4, 2018 Category: Pharmaceuticals Source Type: news

With Hemlibra, Roche seeks to break into tight hemophilia circle
Swiss drugmaker Roche is breaking into hemophilia A treatment, a $10 billion global market dominated by rivals who have cultivated close ties to sufferers of the genetic bleeding disorder. (Source: Reuters: Health)
Source: Reuters: Health - October 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

EU Panel Backs Damoctocog Alfa Pegol for Hemophilia A EU Panel Backs Damoctocog Alfa Pegol for Hemophilia A
The EMA's CHMP recommended damoctocog alfa pegol (Jivi, Bayer AG) for the treatment and prophylaxis of bleeding in patients aged 12 years and older who have been previously treated for hemophilia A.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 24, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

21.09.18: Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for its hemophilia A treatment BAY94-9027The safety and efficacy profile of BAY94-9027 has been demonstrated in more than five years of clinical studies / Prophylaxis with BAY94-9027 enables sustained factor VIII concentrations in the blood over timemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 21, 2018 Category: Pharmaceuticals Source Type: news

Bayer receives positive CHMP opinion for its hemophilia A treatment BAY94-9027 (for specialized target groups only)
The safety and efficacy profile of BAY94-9027 has been demonstrated in more than five years of clinical studies / Prophylaxis with BAY94-9027 enables sustained factor VIII concentrations in the blood over time (Source: Bayer Company News)
Source: Bayer Company News - September 21, 2018 Category: Pharmaceuticals Source Type: news

Bayer hemophilia treatment wins thumbs-up from EU panel
Bayer AG's long-acting treatment for hemophilia A has won a recommendation from a European Medicines Agency (EMA) panel for the treatment of the rare genetic disorder in which blood does not clot easily. (Source: Reuters: Health)
Source: Reuters: Health - September 21, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Bayer & #8217;s Jivi ® approved in Japan for hemophilia A (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - September 21, 2018 Category: Pharmaceuticals Source Type: news

21.09.18: Not intended for U.S. and UK Media
Bayer's Jivi® approved in Japan for hemophilia Amehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 20, 2018 Category: Pharmaceuticals Source Type: news

Patent mining indicates promising routes for research
(Funda ç ã o de Amparo à Pesquisa do Estado de S ã o Paulo) Methodology developed by Brazilian scientists uses big data tools, has been validated in an analysis of studies on hemophilia, and can also be used to search for partnerships and technology transfer opportunities. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 31, 2018 Category: International Medicine & Public Health Source Type: news

Bayer wins FDA ok for hemophilia drug
Bayer AG has received U.S. FDA approval for a Factor VIII hemophilia drug, called Jivi. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 31, 2018 Category: Pharmaceuticals Source Type: news

FDA Clears New Hemophilia A Drug With Flexible Dosing FDA Clears New Hemophilia A Drug With Flexible Dosing
Jivi (antihemophilic factor [recombinant] PEGylated-aucl) is for routine prophylactic treatment, on-demand treatment, and perioperative management of bleeding in adults and in adolescents 12 and older.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 30, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Bayer Receives FDA Approval for Jivi (antihemophilic factor (recombinant), PEGylated-aucl) for Prophylactic Treatment of Hemophilia A
WHIPPANY, N.J., Aug. 30, 2018 /PRNewswire/ -- Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Jivi ® (BAY94-9027, antihemophilic factor [recombinant] PEGylated-aucl) for the routine prophylactic treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 30, 2018 Category: Drugs & Pharmacology Source Type: news

30.08.18: Not intended for U.S. and UK Media
Bayer receives US approval for modern hemophilia A treatment Jivi® with a step-wise prophylaxis dosing regimenJivi's extended half-life allows for twice-weekly initial dosing / May be adjusted to every five days and further individually adjusted to less or more frequent dosingmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 30, 2018 Category: Pharmaceuticals Source Type: news

Morning Break: Acne Vax; Jivi OK'd for Hemophilia; Gottlieb, Coffee, and Cancer
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - August 30, 2018 Category: OBGYN Source Type: news

Bayer's hemophilia A treatment gets U.S. FDA approval
The U.S. Food and Drug Administration on Thursday approved Bayer AG's long-acting treatment for hemophilia A, a rare genetic disorder in which blood does not clot easily, the company said in a statement. (Source: Reuters: Health)
Source: Reuters: Health - August 30, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Bayer's hemophilia A drug gets FDA approval
The U.S. Food and Drug Administration on Thursday approved Bayer AG's drug for the treatment of hemophilia A, a rare genetic disorder in which the blood does not clot normally, the company said in a statement. (Source: Reuters: Health)
Source: Reuters: Health - August 30, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Bayer receives US approval for modern hemophilia A treatment Jivi ® with a step-wise prophylaxis dosing regimen (for specialized target groups only)
Jivi’s extended half-life allows for twice-weekly initial dosing / May be adjusted to every five days and further individually adjusted to less or more frequent dosing (Source: Bayer Company News)
Source: Bayer Company News - August 30, 2018 Category: Pharmaceuticals Source Type: news

Positive phase III results for Roche ’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine
Roche today announced that pivotal data from the phase III HAVEN 3 study, which evaluated Hemlibra ® (emicizumab) prophylaxis administered every week or every two weeks in adults and adolescents aged 12 years or older with haemophilia A without factor VIII inhibitors, were published in the 30 August 2018 issue of the New England Journal of Medicine (NEJM). (Source: Roche Media News)
Source: Roche Media News - August 30, 2018 Category: Pharmaceuticals Source Type: news

Positive phase III results for Roche ’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine
Roche today announced that pivotal data from the phase III HAVEN 3 study, which evaluated Hemlibra ® (emicizumab) prophylaxis administered every week or every two weeks in adults and adolescents aged 12 years or older with haemophilia A without factor VIII inhibitors, were published in the 30 August 2018 issue of the New England Journal of Medicine (NEJM). (Source: Roche Investor Update)
Source: Roche Investor Update - August 30, 2018 Category: Pharmaceuticals Source Type: news

Study by blood doctors a breakthrough for hemophiliacs
(University of the Witwatersrand) The HAVEN 3 study found that a new type of protein, emicizumab (trade name: Hemlibra), can be administered subcutaneously, rather than intravenously, and that it does not cause an immune response which prevents blood from clotting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 30, 2018 Category: International Medicine & Public Health Source Type: news